10-Q: Compass Therapeutics Reports Q3 2024 Results, Provides Clinical Pipeline Update

Compass Therapeutics reported its Q3 2024 financial results and provided updates on its clinical development programs, including discontinuing a Phase 2 trial for CTX-009 and planning a new trial.

Summary

• Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its financial results for the third quarter of 2024, ending September 30.
• The company reported a net loss of $10.48 million for the quarter, compared to a net loss of $9.96 million for the same period in 2023.
• For the nine months ended September 30, 2024, the net loss was $34.34 million, compared to $29.08 million for the same period in 2023.
• Licensing revenue for the nine months ended September 30, 2024 was $850,000, stemming from a milestone payment from Elpiscience.
• Research and development expenses increased to $29.3 million for the nine months ended September 30, 2024, up from $25.69 million in the same period of 2023.
• General and administrative expenses also increased to $11.6 million for the nine months ended September 30, 2024, up from $9.28 million in the same period of 2023.
• As of September 30, 2024, Compass had $135 million in cash and marketable securities, which the company expects will fund operations into the first quarter of 2027.
• The company discontinued a Phase 2 monotherapy trial of CTX-009 in metastatic colorectal cancer due to not meeting pre-determined response criteria.
• Compass is planning to initiate a new second-line trial in patients with metastatic colorectal cancer combined with chemotherapy whose tumors express DLL4 in mid-2025.
• A Phase 2/3 trial for CTX-009 in combination with paclitaxel in biliary tract cancer is fully enrolled, with top-line data expected at the end of the first quarter of 2025.
• The company also reported that a combination study of CTX-471 with KEYTRUDA was discontinued due to unexpected suppression of proinflammatory cytokines.
• A Phase 1a trial of CTX-8371 is ongoing, with the second cohort completed and the third cohort planned by the end of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a solid cash position and is progressing with some clinical trials, the discontinuation of a Phase 2 trial and a combination study is concerning. The need for potential future capital raises also adds uncertainty.

Positives

• The company has sufficient cash and marketable securities to fund operations into the first quarter of 2027.
• The Phase 2/3 trial of CTX-009 in biliary tract cancer is fully enrolled, with top-line data expected in Q1 2025.
• The Phase 1a trial of CTX-8371 is progressing, with the second cohort completed and the third cohort planned by the end of 2024.
• The company received a $1 million milestone payment from Elpiscience for completing a Phase 1 trial in China.

Negatives

• The company reported a net loss of $10.48 million for Q3 2024 and $34.34 million for the nine months ended September 30, 2024.
• A Phase 2 monotherapy trial of CTX-009 in metastatic colorectal cancer was discontinued due to not meeting response criteria.
• A combination study of CTX-471 with KEYTRUDA was discontinued due to unexpected suppression of proinflammatory cytokines.

Risks

• The company is dependent on the successful development and commercialization of its treatments.
• The company has incurred significant operating losses since inception and has not generated any revenue from the sale of products.
• The company may need to raise additional capital through equity or debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties.
• The company faces numerous risks and uncertainties associated with product development and commercialization.
• The company may be required to delay, limit, reduce or terminate its research, product development or future commercialization efforts if it is unable to raise additional funds.

Future Outlook

The company expects its cash resources will enable it to fund operating expenses and capital expenditure requirements into the first quarter of 2027. The company plans to initiate a new second-line trial in patients with metastatic colorectal cancer combined with chemotherapy whose tumors express DLL4 in mid-2025. Top-line data from the Phase 2/3 trial for CTX-009 in biliary tract cancer is expected at the end of the first quarter of 2025. The company plans to initiate the third cohort of the CTX-8371 trial by the end of 2024.

Management Comments

• The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.
• The company intends to explore the potential of CTX-009 in additional indications based on data from pre-clinical models, potential biomarkers such as DLL4, and clinical data from CTX-009 trials providing signs of potential activity of CTX-009.
• The company is currently evaluating the design for its next study of CTX-471 using NCAM as a biomarker, which it expects to initiate in mid-2025.

Industry Context

The company is operating in a competitive biotechnology and pharmaceutical industry, focusing on oncology and antibody-based therapeutics. The company's pipeline targets angiogenesis and immune-oncology pathways, which are areas of significant interest in cancer research and drug development. The company's decision to discontinue a trial and initiate a new one reflects the dynamic nature of clinical development and the need to adapt strategies based on emerging data.

Comparison to Industry Standards

• The reported net losses are typical for clinical-stage biopharmaceutical companies that are heavily investing in research and development.
• The cash runway into Q1 2027 is a positive sign, indicating a relatively stable financial position compared to other companies in the sector.
• The decision to discontinue the Phase 2 monotherapy trial of CTX-009 is not uncommon in drug development, as companies often need to pivot based on clinical results.
• The company's focus on bispecific antibodies and immune-oncology agents aligns with current trends in cancer therapeutics, with companies like Regeneron, Amgen, and Roche also heavily invested in these areas.
• The company's approach to combining CTX-009 with chemotherapy is a common strategy in oncology, similar to approaches taken by companies like Merck and Bristol Myers Squibb.
• The company's use of biomarkers like NCAM to guide patient selection in clinical trials is a growing trend in personalized medicine, similar to strategies employed by companies like Foundation Medicine and Guardant Health.

Stakeholder Impact

• Shareholders may be concerned about the discontinued trials and the need for potential future capital raises.
• Employees may be affected by changes in the company's clinical development strategy.
• Customers (potential patients) may be impacted by the changes in the clinical pipeline.
• Suppliers and creditors may be affected by the company's financial performance and future funding requirements.

Next Steps

• Initiate a new second-line trial in patients with metastatic colorectal cancer combined with chemotherapy whose tumors express DLL4 in mid-2025.
• Report top-line data from the Phase 2/3 trial for CTX-009 in biliary tract cancer at the end of the first quarter of 2025.
• Initiate the third cohort of the CTX-8371 trial by the end of 2024.
• Evaluate the design for its next study of CTX-471 using NCAM as a biomarker, which it expects to initiate in mid-2025.

Key Dates

Keywords

Compass Therapeutics, biopharmaceutical, oncology, antibody therapeutics, clinical trials, CTX-009, CTX-471, CTX-8371, colorectal cancer, biliary tract cancer, immunotherapy, DLL4, VEGF-A, CD137, PD-1, PD-L1